NeuroSense Therapeutics signs strategic collaboration agreement to advance PrimeC supply for ALS patients
NRSN•NeuroSense Therapeutics signed a strategic collaboration agreement to advance PrimeC supply for ALS patients and targets first PrimeC revenues in the first half of 2027.
1. Collaboration and revenue target
A securities filing says Neurosense Therapeutics Ltd signed a strategic collaboration agreement to advance PrimeC supply for ALS patients. The company targets first PrimeC revenues in the first half of 2027.
